X4 Pharma Q1 net loss $24M; cash $94.4M funds ops into Q2 2024; WHIM NDA on track

X4 Pharmaceuticals, Inc

2022-Q3 EPS reported -$0.16

Cash, cash equivalents, and restricted cash of $94.4M as of March 31, 2023, sufficient into Q2 2024.
R&D expenses $22.1M (up from $14.1M YoY) including $5.0M accrual for probable in-licensing milestone.
Net loss $24.0M vs $22.0M YoY; includes $1.6M stock compensation and $5.4M gain on warrant liability.
U.S. NDA submission for mavorixafor in WHIM syndrome on track for early second half 2023.
Phase 2 chronic neutropenia data and regulatory path update anticipated in Q2/Q3 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

X4 Pharmaceuticals, Inc reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

X4 Pharmaceuticals Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2023

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001628280-23-015494

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.